

THE KING OF CANNABIS EXPORTS



The King of Cannabis Exports

At the *National Institute for Cannabis Investors*, we're constantly looking at what's ahead for the cannabis industry.

Right now, most cannabis is being exported from Canada.

But in the future, that's all going to change.

Cannabis will either mostly be grown in a lab or in parts of the world where labor is cheap and the conditions for growing are ideal.

Cannabis is a plant that likes a lot of light, needs the right balance of rain and sun, and thrives at high altitudes. With the right conditions, THC cannabis can be a large outdoor crop. Growing outdoors is still expensive, but with all the equipment and maintenance, running an indoor operation can cost a small fortune.

We don't know for sure which way will be the most popular in terms of growing cannabis, but we do know that **Latin America** is starting to build an important foothold in the marijuana market.

And the world's cannabis companies see this coming and are already taking steps to make the transition. Most large Canadian producers have at least one or two deals to produce cannabis in South America or the Caribbean.

Similar to how farmers in the **United States** are starting to grow hemp as a cash crop, coffee exporters and flower growers could also use some of their land to start growing cannabis.

According to **New Frontier Data**, the Latin American market for legal and illicit cannabis is worth \$9.8 billion right now...

Compare that to the industry in **North America** that was worth \$10 billion in 2018.

Today, we're going to take a look at a few of the key markets in Latin America that could eventually generate massive sales in cannabis exports.

Brazil

Currently, there's an estimated 4.2 million people who use cannabis in Brazil.

The market for cannabis users is going to be even bigger since Brazil has the largest population in Latin America.

Cultivation in small amounts is decriminalized, and the medical program the country has set up is very strict. The "cannabis" that is allowed for medical use is CBD-only.

However, activism was what helped get even just CBD allowed in the first place.

A mother fought to get CBD-based products allowed in the country so that her five-year-old daughter could have a treatment for her epilepsy.

Colombia

Colombia – a country nestled in the northwestern region of South America – is known for four things...

Coffee

White, sandy beaches...

The world's largest coastal mountain range...

And "Colombian Gold."

The South American sovereign state is known for producing some of the most potent pot on the planet.

Eventually, Colombia on its own could capture a fifth of the global cannabis market, which is expected to be worth \$40 billion a year.

The country has a 12-hour light cycle, and open-air greenhouses are a staple.

This allows for lower energy costs compared to typical indoor cultivation setups.

And as of February 2019, 68 of the 73 manufacturing licenses are authorized to manufacture for export.

PharmaCielo is an early leader in Colombian cannabis production. In fact, this small medical marijuana producer was the first to grow legal cannabis in the region.

Since then, it has rapidly become the largest grower in Colombia, and it has a massive expansion plan, which could make it the *largest cannabis grower in the world*.

And PharmaCielo's cost advantage compared to U.S. and Canadian growers is why this company deserves your attention. By the time Canadian companies can get cannabis production costs to less than \$1 per gram, PharmaCielo will be doing it for closer to \$0.05 cents per gram.

It will start selling cannabis in Colombia – and it will expand to Mexico, Brazil, and Europe. Most countries in the EU are relying on Canada for medical marijuana, but it won't be that way much longer if PharmaCielo has its way.

Mexico

Some have estimated that Mexico could reach \$11 billion in annual cannabis sales by 2030 if it gets a legal framework up and running. This is going to be a huge market, and it could force the U.S. to legalize cannabis sooner rather than later.

Uruguay

Uruguay was the first country in the world to legalize marijuana.

It hasn't received as much attention as when Canada legalized cannabis in 2018 for a few reasons

The first is that Uruguay faced significant amounts of supply shortages when it first launched. There were also issues with early batches of the legal cannabis that was grown without passing tests for genetics, mold, bacteria, pesticides, and other contaminants.

Sales are also restricted to Uruguayan citizens and permanent residents.

On top of all that, as of April, only 17 pharmacies were selling cannabis to the country's 3.5 million inhabitants.

There are also only four different strains available to buy.

However, establishing a legal framework is very important, and this will help other countries in Latin America get their own markets up and running. They can see what worked.

They can also see what didn't work and avoid the same mistakes as Uruguay.

Conclusion on the Latin American Cannabis Markets

We still believe there is a tremendous amount of money to be made from the U.S. and Canadian markets.

By the time a significant shift happens in where the majority of cannabis is grown, U.S. and Canadian growers will have made so much money that it won't matter if most of the world's cannabis is being grown and shipped from Latin America.

However, because this is going to be such an explosive opportunity, we wanted to make sure our readers knew about the Latin American markets now.

To your investing success,

The National Institute for Cannabis Investors

<u>Please Note</u>: From time to time, the National Institute for Cannabis Investors, LLC will recommend stocks or other investments that will not be included in our regular portfolios. There are certain situations where we feel a company may be an extraordinary value but may not necessarily fit within the selection guidelines of these existing portfolios. In these cases, the recommendations are speculative and should not be considered as part of the National Institute for Cannabis Investors, LLC philosophy.

Also, by the time you receive this report, there is a chance that we may have exited a recommendation previously included in our portfolio. Occasionally, this happens because we use a disciplined selling strategy with our investments, meaning that if a company's share price falls below a certain price level, we immediately notify our subscribers to sell the stock.

NOTE: National Institute for Cannabis Investors, LLC is not a broker, dealer or licensed investment advisor. No person listed here should be considered as permitted to engage in rendering personalized investment, legal or other professional advice as an agent of National Institute for Cannabis Investors, LLC. National Institute for Cannabis Investors, LLC does not receive any compensation for these services. Additionally, any individual services rendered to subscribers by those mentioned are considered completely separate from and outside the scope of services offered by National Institute for Cannabis Investors, LLC. Therefore if you choose to contact anyone listed here, such contact, as well as any resulting relationship, is strictly between you and them.



Copyright 2007-present, National Institute for Cannabis Investors, LLC 1125 N. Charles Street, Baltimore, MD 21201
Phone: 866.260.0361

All rights reserved. National Institute for Cannabis Investors, LLC provides its members with unique opportunities to build and protect wealth, globally, under all market conditions.

The executive staff, research department and editors who contribute to National Institute for Cannabis Investors, LLC recommendations are proud of our history and reputation. We believe the advice presented to our subscribers in our published resources and at our meetings and seminars is the best and most useful available to global investors today. The recommendations and analysis presented to members is for the exclusive use of members. Copying or disseminating any information published by National Institute for Cannabis Investors, LLC, electronic or otherwise, is strictly prohibited. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. Likewise, past performance does not assure future results. Recommendations are subject to change at any time, so members are encouraged to make regular use of the website and pay special attention to National Institute for Cannabis Investors, LLC updates sent out via e-mail. The publishers, editors, employees or agents are not responsible for errors and/or omissions.

PRIVACY NOTICE

You and your family are entitled to review and act on any recommendations made in this document. All National Institute for Cannabis Investors, LLC publications are protected by copyright. No part of this report may be reproduced by any means (including facsimile) or placed on any electronic medium without written permission from the publisher. Information contained herein is obtained from sources believed to be reliable, but its accuracy cannot be guaranteed. National Institute for Cannabis Investors, LLC expressly forbids its writers from having a financial interest in any security recommended to its readers. All National Institute for Cannabis Investors, LLC employees and agents must wait 24 hours after an Internet publication and 72 hours after a print publication is mailed prior to following an initial recommendation. National Institute for Cannabis Investors, LLC does not act as a personal investment advisor, nor does it advocate the purchase or sale of any security or investment for any specific individual. Investments recommended in this publication should be made only after consulting with your investment advisor, and only after reviewing the prospectus or financial statements of the company.

National Institute for Cannabis Investors, LLC $\, \bullet \,$ 1125 N. Charles Street $\, \bullet \,$ Baltimore, MD 21201 $\, \bullet \,$ 866.260.0361

NICI1019-1573 WEB